OPRK1 and atherosclerosis: Despite this association, it remains unknown whether nalmefene, an antagonist of mu- and delta-opioid receptors and a partial agonist of the kappa-opioid receptor, contributes to the development of atherosclerosis and an increased risk of serious cardiovascular events.